Quantum BioPharma (QNTM)
Develops clinical-stage treatments while retaining investments and consumer-product economics.
Something off on this page? Send us feedback.
Develops experimental treatments led by Lucid-MS for multiple sclerosis, alongside FSD-PEA for mast-cell activation syndrome. The company also reports a strategic-investments segment and retains economic interests in unbuzzd, a spun-out consumer product.
Clinical-stage development centers on Lucid-MS, an investigational compound directed at myelin degradation in multiple sclerosis. FSD-PEA is also in development for mast-cell activation syndrome, within a portfolio that targets neurodegenerative, inflammatory, metabolic, and alcohol-misuse disorders.
A separately reported strategic-investments segment sits alongside biopharmaceutical R&D. The company retained ownership and royalty economics in unbuzzd after spinning its consumer rights into Unbuzzd Wellness, while keeping pharmaceutical and medical-formulation rights.
From Toronto, founder and CEO Zeeshan Saeed leads the company. Progress depends on clinical development, regulatory authorization, financing, intellectual-property protection, and continued exchange-listing compliance.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.7M · Total debt $962.2K · Total assets $14.4M · Shareholders' equity $7.9M
- Revenue
- $0
- Operating income
- −$2.2M
- Net income
- −$3.2M
No dividends on record.
| Institutions | 6.49% | 415.1K shares | |
|---|---|---|---|
| 27 holders · as of Jun 30, 2026 | |||
| Other | 93.51% | 5.98M shares | |
| remainder | |||
6.40M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Advisorshares Investments LLCInstitution | 3.18% | 203,564 | as of Jun 30, 2026 |
Jane Street Group, LLCInstitution | 0.76% | 48,355 | as of Jun 30, 2026 |
Platform Technology PartnersInstitution | 0.64% | 41,116 | as of Jun 30, 2026 |
UBS Group AGInstitution | 0.52% | 33,405 | as of Jun 30, 2026 |
Steward Partners Investment Advisory, LLCInstitution | 0.44% | 27,881 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Novartis (ADR)
Approved and pipeline therapies spanning relapsing and progressive MS
- Biogen
Established portfolio of marketed multiple-sclerosis therapies
- TG Therapeutics
Commercial and clinical programs across relapsing and progressive MS
- Immunic
Late-stage oral therapy program for relapsing and progressive MS
- Clene
Clinical remyelination and neuroprotection programs in multiple sclerosis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Quantum BioPharma | $4.14 | +11.89% | $23.7M | — | — | — | — |
| Novartis (ADR) | $142.63 | +0.95% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Biogen | $223.12 | −1.00% | $33.30B | 39.9 | 16.8 | 3.3 | +3.4% |
| TG Therapeutics | $55.36 | −4.74% | $8.90B | 21.2 | 29.1 | 11.1 | +70.3% |
| Immunic | $9.54 | −11.99% | $147.7M | — | — | — | — |
| Clene | $4.36 | −0.57% | $56.0M | — | — | 284.1 | +233.3% |
| Median | 21.3 | 16.8 | 8.0 | +36.8% |